With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
We are looking for an experienced and motivated DMPK Scientist to take on a critical project leadership role in our growing team and contribute to our organisation's DMPK strategy. You will be the DMPK lead on small molecule discovery programs in a broad range of disease areas. BenevolentAI will provide the development and learning opportunities for you to progress your career into DMPK specialisms such as PBPK modelling. Working with industry leaders in medicinal chemistry, in vitro and in vivo pharmacology and toxicology, you will have the support and independence to strategise, innovate and make key contributions to overall DMPK effort at BenevolentAI. Your decisions and impact on these projects will have a tangible effect on the progression of clinical candidates.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email email@example.com. Thank you.